Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease
- PMID: 20075088
- PMCID: PMC2821467
- DOI: 10.3174/ajnr.A1809
Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease
Abstract
Background and purpose: Different biomarkers for AD may potentially be complementary in diagnosis and prognosis of AD. Our aim was to combine MR imaging, FDG-PET, and CSF biomarkers in the diagnostic classification and 2-year prognosis of MCI and AD, by examining the following: 1) which measures are most sensitive to diagnostic status, 2) to what extent the methods provide unique information in diagnostic classification, and 3) which measures are most predictive of clinical decline.
Materials and methods: ADNI baseline MR imaging, FDG-PET, and CSF data from 42 controls, 73 patients with MCI, and 38 patients with AD; and 2-year clinical follow-up data for 36 controls, 51 patients with MCI, and 25 patients with AD were analyzed. The hippocampus and entorhinal, parahippocampal, retrosplenial, precuneus, inferior parietal, supramarginal, middle temporal, lateral, and medial orbitofrontal cortices were used as regions of interest. CSF variables included Abeta42, t-tau, p-tau, and ratios of t-tau/Abeta42 and p-tau/Abeta42. Regression analyses were performed to determine the sensitivity of measures to diagnostic status as well as 2-year change in CDR-SB, MMSE, and delayed logical memory in MCI.
Results: Hippocampal volume, retrosplenial thickness, and t-tau/Abeta42 uniquely predicted diagnostic group. Change in CDR-SB was best predicted by retrosplenial thickness; MMSE, by retrosplenial metabolism and thickness; and delayed logical memory, by hippocampal volume.
Conclusions: All biomarkers were sensitive to the diagnostic group. Combining MR imaging morphometry and CSF biomarkers improved diagnostic classification (controls versus AD). MR imaging morphometry and PET were largely overlapping in value for discrimination. Baseline MR imaging and PET measures were more predictive of clinical change in MCI than were CSF measures.
Figures



Similar articles
-
FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.Neuroimage Clin. 2018 Jan 28;18:167-177. doi: 10.1016/j.nicl.2018.01.019. eCollection 2018. Neuroimage Clin. 2018. PMID: 29387532 Free PMC article.
-
Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.J Alzheimers Dis. 2020;74(2):473-490. doi: 10.3233/JAD-191109. J Alzheimers Dis. 2020. PMID: 32039853
-
Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.Alzheimers Res Ther. 2017 Apr 26;9(1):32. doi: 10.1186/s13195-017-0260-z. Alzheimers Res Ther. 2017. PMID: 28441967 Free PMC article.
-
Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.J Lab Autom. 2015 Oct;20(5):589-600. doi: 10.1177/2211068214559979. Epub 2014 Nov 25. J Lab Autom. 2015. PMID: 25424384 Review.
-
Concordance between brain 18F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease.Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Jan-Feb;37(1):3-8. doi: 10.1016/j.remn.2017.05.003. Epub 2017 Jun 20. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018. PMID: 28645685 Review. English, Spanish.
Cited by
-
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.Radiology. 2013 Feb;266(2):583-91. doi: 10.1148/radiol.12120010. Epub 2012 Dec 11. Radiology. 2013. PMID: 23232293 Free PMC article.
-
Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights.J Pers Med. 2020 Jul 10;10(3):61. doi: 10.3390/jpm10030061. J Pers Med. 2020. PMID: 32664352 Free PMC article. Review.
-
Sparse reduced-rank regression detects genetic associations with voxel-wise longitudinal phenotypes in Alzheimer's disease.Neuroimage. 2012 Mar;60(1):700-16. doi: 10.1016/j.neuroimage.2011.12.029. Epub 2011 Dec 22. Neuroimage. 2012. PMID: 22209813 Free PMC article.
-
Cross contrast multi-channel image registration using image synthesis for MR brain images.Med Image Anal. 2017 Feb;36:2-14. doi: 10.1016/j.media.2016.10.005. Epub 2016 Oct 22. Med Image Anal. 2017. PMID: 27816859 Free PMC article.
-
Significance of normalization on anatomical MRI measures in predicting Alzheimer's disease.ScientificWorldJournal. 2014 Jan 6;2014:541802. doi: 10.1155/2014/541802. eCollection 2014. ScientificWorldJournal. 2014. PMID: 24550710 Free PMC article.
References
-
- Mosconi L, Brys M, Glodzik-Sobanska L, et al. . Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007;42:129–38 - PubMed
-
- Blennow K, Wallin A, Agren H, et al. . Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231–45 - PubMed
-
- Andreasen N, Blennow K. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 2002;23:1205–14 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical